Neumora Therapeutics’ (NMRA) Outperform Rating Reiterated at William Blair

William Blair reissued their outperform rating on shares of Neumora Therapeutics (NASDAQ:NMRA) in a research report report published on Wednesday morning,RTT News reports.

A number of other analysts also recently issued reports on NMRA. Royal Bank of Canada downgraded Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and cut their target price for the stock from $29.00 to $4.00 in a research note on Thursday, January 2nd. JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $18.00 to $15.00 in a research note on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Neumora Therapeutics in a research note on Friday, January 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a research report on Thursday, January 2nd. Finally, Bank of America lowered their price objective on Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Neumora Therapeutics Trading Down 5.5 %

NMRA opened at $2.05 on Wednesday. Neumora Therapeutics has a twelve month low of $1.83 and a twelve month high of $21.00. The firm has a market capitalization of $331.20 million, a PE ratio of -1.10 and a beta of 2.71. The firm’s 50-day moving average price is $8.74 and its 200 day moving average price is $11.05.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same period last year, the business posted ($1.14) earnings per share. As a group, analysts predict that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Neumora Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its position in Neumora Therapeutics by 2.6% in the third quarter. JPMorgan Chase & Co. now owns 64,421 shares of the company’s stock valued at $851,000 after purchasing an additional 1,629 shares during the period. Barclays PLC boosted its holdings in Neumora Therapeutics by 352.9% during the 3rd quarter. Barclays PLC now owns 129,210 shares of the company’s stock valued at $1,708,000 after acquiring an additional 100,678 shares during the period. Geode Capital Management LLC boosted its holdings in Neumora Therapeutics by 54.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock valued at $26,159,000 after acquiring an additional 694,385 shares during the period. Wexford Capital LP grew its position in Neumora Therapeutics by 90.1% in the 3rd quarter. Wexford Capital LP now owns 217,879 shares of the company’s stock valued at $2,878,000 after acquiring an additional 103,285 shares in the last quarter. Finally, State Street Corp increased its stake in Neumora Therapeutics by 65.3% during the third quarter. State Street Corp now owns 1,790,707 shares of the company’s stock worth $23,655,000 after purchasing an additional 707,409 shares during the period. Hedge funds and other institutional investors own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.